MX2022016516A - Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. - Google Patents
Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.Info
- Publication number
- MX2022016516A MX2022016516A MX2022016516A MX2022016516A MX2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- exhibitng
- diones
- pyridine
- mnk
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046325P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/039982 WO2022006331A2 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibitng mnk inhibition and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016516A true MX2022016516A (es) | 2023-03-28 |
Family
ID=79315594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016516A MX2022016516A (es) | 2020-06-30 | 2021-06-30 | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230286983A1 (https=) |
| EP (1) | EP4171565A4 (https=) |
| JP (1) | JP2023533616A (https=) |
| KR (1) | KR20230041715A (https=) |
| CN (1) | CN116194112A (https=) |
| AU (1) | AU2021300363A1 (https=) |
| BR (1) | BR112022026275A2 (https=) |
| CA (1) | CA3183551A1 (https=) |
| IL (1) | IL299512A (https=) |
| MX (1) | MX2022016516A (https=) |
| WO (1) | WO2022006331A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225747A1 (en) * | 2021-06-30 | 2023-01-05 | 4E Therapeutics, Inc. | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| CN103874496A (zh) * | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017068064A1 (en) * | 2015-10-22 | 2017-04-27 | Selvita S.A. | Pyridone derivatives and their use as kinase inhibitors |
| BR112018008711A2 (pt) * | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2 |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017165908A1 (en) * | 2016-03-31 | 2017-10-05 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| CN113286592A (zh) * | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110256432A (zh) * | 2019-06-27 | 2019-09-20 | 诺沃斯达药业有限公司 | 抑制mnk1和mnk2的多环化合物 |
-
2021
- 2021-06-30 JP JP2023524490A patent/JP2023533616A/ja active Pending
- 2021-06-30 WO PCT/US2021/039982 patent/WO2022006331A2/en not_active Ceased
- 2021-06-30 BR BR112022026275A patent/BR112022026275A2/pt unknown
- 2021-06-30 MX MX2022016516A patent/MX2022016516A/es unknown
- 2021-06-30 CA CA3183551A patent/CA3183551A1/en active Pending
- 2021-06-30 IL IL299512A patent/IL299512A/en unknown
- 2021-06-30 US US18/003,829 patent/US20230286983A1/en active Pending
- 2021-06-30 CN CN202180056845.0A patent/CN116194112A/zh active Pending
- 2021-06-30 KR KR1020237003174A patent/KR20230041715A/ko active Pending
- 2021-06-30 AU AU2021300363A patent/AU2021300363A1/en active Pending
- 2021-06-30 EP EP21831750.1A patent/EP4171565A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183551A1 (en) | 2022-01-06 |
| WO2022006331A3 (en) | 2022-02-10 |
| EP4171565A2 (en) | 2023-05-03 |
| EP4171565A4 (en) | 2024-11-27 |
| CN116194112A (zh) | 2023-05-30 |
| US20230286983A1 (en) | 2023-09-14 |
| KR20230041715A (ko) | 2023-03-24 |
| WO2022006331A9 (en) | 2022-03-03 |
| JP2023533616A (ja) | 2023-08-03 |
| WO2022006331A8 (en) | 2023-03-16 |
| WO2022006331A2 (en) | 2022-01-06 |
| IL299512A (en) | 2023-02-01 |
| AU2021300363A1 (en) | 2023-02-09 |
| BR112022026275A2 (pt) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| MX2024000028A (es) | Piridin-1,5-dionas espirocíclicas que exhiben inhibición de la proteína cinasa activada por mitógenos (mnk) y su método de uso. | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2020011294A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina. | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| PH12022553024A1 (en) | Inhibitors of nek7 kinase | |
| MX2022016516A (es) | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. | |
| MX2026003002A (es) | Inhibidores de kras | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| MY207787A (en) | Alpha-d-galactopyranoside derivatives | |
| MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2022015495A (es) | Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2024010782A (es) | Agentes ligadores de fenil maleimida | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) |